The abstract mentions examining effects in patients both with and without diabetes, but doesn't clarify outcomes in non-diabetic populations. This distinction is crucial for determining whether benefits are diabetes-specific or represent broader neuroprotective mechanisms applicable to all dementia patients. Gap type: open_question Source paper: GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. (2023, Diabetes & metabolism, PMID:37657738)
Landscape Summary: Do GLP-1 agonists provide neuroprotection in non-diabetic patients with neurodegeneration? is a 0.79 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Do GLP-1 agonists provide neuroprotection in non-diabetic patients with neurodegeneration? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: